Journal of Health Sciences and Medicine

Yazarlar: Gülçin ERTAŞ, Ali Rıza ÜÇER, Can AZAK, Muzaffer Bedri ALTUNDAĞ

Konular:Sağlık Bilimleri ve Hizmetleri

DOI:10.32322/jhsm.975342

Anahtar Kelimeler:Malignant Glioma,Hypofractionated Dose,Chemotherapy,Elderly

Özet: Aim: The aim of this study is to examine the treatment results of 25 malign glioma patients, aged >60 who underwent hypofractionated radiotherapy, respectively. Material and Method: Total excision was applied to 14 of the patients, subtotal excision was applied to 5 and biopsy was applied only to 3. Three patients were evaluated as inoperable. Pathological diagnosis is compatible with glioblastoma in 22 patients, gliosarcoma in 2 patients and anaplastic astrocytoma in 1 patient. Hypofractionated radiotherapy was applied to all patients in the dose range 2.66-3.4 Gy x 10-15 fractions. Ten patients were treated concurrent temozolomide with radiotherapy and then 4-6 cures of adjuvant temozolomide. Only concurrent temozolomide treatment was applied to 3 patients, while only adjuvant temozolomide was applied to 4 patients. Results: The median age is 72 years. (min 60–max 86) . The rate of patients with comorbid disease is 44%. The median follow-up period of the patients is 5 months (min 1-max 22). 6-months, 1-year, 18-months overall survival were 47%, 20%, 10%, respectively. Median survival in patients aged >70 is 3 months and 8 months in patients <70 (p=0.025). Median survival is 10 months in patients receiving both concurrent and adjuvant temozolomide treatment, and median survival is 3 months (p=0.007) in patients who do not receive it. Conclusion: Overall survival is statistically better in patients under the age of 70 and patients receiving both concurrent and adjuvant temozolomide therapy with hypofractionated radiotherapy.

---